The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body radiation therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC).
 
Parul Agarwal
No Relationships to Disclose
 
Hanfei Qi
No Relationships to Disclose
 
Kabeer Munjal
No Relationships to Disclose
 
Jessica Gai
No Relationships to Disclose
 
Anna Ferguson
No Relationships to Disclose
 
Rose Parkinson
No Relationships to Disclose
 
Jeanne Harrison
No Relationships to Disclose
 
Christina Rodriguez
No Relationships to Disclose
 
Robert A. Anders
Employment - Johns Hopkins Hospital
Honoraria - Peerview
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; Merck
Research Funding - Bristol-Myers Squibb/Medarex; RAPT Therapeutics; Stand up to Cancer
 
Elizabeth D. Thompson
No Relationships to Disclose
 
Richard Burkhart
No Relationships to Disclose
 
Jin He
No Relationships to Disclose
 
Amol Narang
Research Funding - Boston Scientific; Nanocan Therapeutics
 
Ana De Jesus-Acosta
Consulting or Advisory Role - Merck
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Lei Zheng
No Relationships to Disclose
 
Elizabeth M. Jaffee
No Relationships to Disclose
 
Ben George
No Relationships to Disclose
 
Daniel A. Laheru
No Relationships to Disclose
 
Mark Yarchoan
Leadership - Adventris Pharmaceuticals
Stock and Other Ownership Interests - Adventris Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
Arsen Osipov
No Relationships to Disclose